tiprankstipranks
Cizzle Biotech Nears Major US Licensing Deal
Company Announcements

Cizzle Biotech Nears Major US Licensing Deal

Cizzle Biotechnology Holdings PLC (GB:CIZ) has released an update.

Pick the best stocks and maximize your portfolio:

Cizzle Biotechnology Holdings PLC, a UK-based diagnostics developer, is nearing the completion of a strategic licensing agreement in North America with Cizzle Bio Inc., focusing on the marketization of their CIZ1B biomarker for early lung cancer detection. The deal will build upon Cizzle’s recent collaborative efforts, including a significant partnership with Moffitt Cancer Center for testing patients with lung nodules. The company’s innovative blood test aims to offer a non-intrusive and cost-effective solution for early-stage cancer detection, leveraging collaborations with prominent cancer centers.

For further insights into GB:CIZ stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskCizzle Biotechnology Enters Strategic North American Partnership
TipRanks UK Auto-Generated NewsdeskCizzle Biotech Advances Lung Cancer Detection
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App